Replimune Group (NASDAQ:REPL) Shares Up 4.4% - Still a Buy?

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) shares shot up 4.4% during trading on Tuesday . The company traded as high as $7.97 and last traded at $7.84. 492,837 shares traded hands during mid-day trading, a decline of 43% from the average session volume of 866,271 shares. The stock had previously closed at $7.51.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. HC Wainwright upped their target price on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. JPMorgan Chase & Co. boosted their price target on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Finally, BMO Capital Markets lifted their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $19.43.

Replimune Group Stock Performance

The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $615.35 million, a P/E ratio of -2.60 and a beta of 1.26. The company has a 50-day moving average price of $10.75 and a two-hundred day moving average price of $11.75.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). Equities analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in REPL. GAMMA Investing LLC increased its position in shares of Replimune Group by 897.2% during the first quarter. GAMMA Investing LLC now owns 8,795 shares of the company's stock valued at $902,000 after buying an additional 7,913 shares during the period. Wellington Management Group LLP raised its holdings in Replimune Group by 352.5% in the 4th quarter. Wellington Management Group LLP now owns 1,096,744 shares of the company's stock worth $13,282,000 after acquiring an additional 854,346 shares during the last quarter. California State Teachers Retirement System boosted its stake in Replimune Group by 25.9% during the 4th quarter. California State Teachers Retirement System now owns 42,725 shares of the company's stock valued at $517,000 after purchasing an additional 8,793 shares during the last quarter. Woodline Partners LP increased its holdings in shares of Replimune Group by 156.6% in the 4th quarter. Woodline Partners LP now owns 854,309 shares of the company's stock worth $10,346,000 after purchasing an additional 521,366 shares in the last quarter. Finally, Velan Capital Investment Management LP purchased a new position in shares of Replimune Group in the fourth quarter worth $2,196,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.